Nexalin Technology Inc. Receives U.S. Patent for Noninvasive DIFS Medical Device to Treat Alzheimer’s and Dementia

Nexalin Technology Inc. Receives U.S. Patent for Innovative Alzheimer’s and Dementia Treatment Device

In a groundbreaking announcement on Thursday, Nexalin Technology Inc. revealed that the United States Patent and Trademark Office had awarded the company U.S. Patent No 12,011,591 for their noninvasive Deep Intracranial Frequency Stimulation (DIFS) medical device. This innovative device is designed to treat Alzheimer’s and other dementia-related brain diseases, marking a significant advancement in the field of neurostimulation technology.

The newly issued patent, titled “Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) Method for Alzheimer’s and Dementia,” specifically pertains to Nexalin’s Gen-2 and Gen-3 brain stimulation medical devices. These devices deliver a proprietary frequency-based waveform to patients in a pain-free and undetectable manner, offering a novel approach to addressing neurological conditions.

Mark White, the CEO of Nexalin Technology, emphasized the importance of their device in light of the growing prevalence of dementia worldwide. He highlighted statistics from Grandview Research and the World Health Organization, noting the significant market potential for innovative treatments like Nexalin’s neurostimulation device.

The Gen-2 and Gen-3 stimulation techniques utilize strategically positioned electrodes on the patient’s cranium to provide deep stimulation to brain regions associated with mental health conditions. This approach has shown promise in treating a range of neurological diseases, from treatment-resistant depression to migraines, anxiety, insomnia, addiction, and PTSD.

Investors responded positively to the news, with NXL shares rising by 36.5% to $1.42 during the premarket session. This surge in stock price reflects the market’s recognition of the potential impact of Nexalin’s DIFS technology on the standard of care for Alzheimer’s and dementia, as well as other mental health disorders.

With the issuance of this patent, Nexalin Technology Inc. is poised to make significant strides in the field of neurostimulation therapy, offering hope to millions of individuals suffering from debilitating brain diseases.